CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a transformative genome editing company, today announced new published research from company co-founder Jennifer A. Doudna, Ph.D., presenting the high-resolution structures of two Cas9 enzymes, extensive single particle electron microscopy (EM) analysis and biochemical data. The researchers present a model in which guide RNA (gRNA) binding triggers Cas9 activation through conformational rearrangement, priming the complex for target DNA binding. The paper was published in the current online edition of Science1 and co-authored by Dr. Doudna, Howard Hughes Medical Institute investigator and professor of biochemistry, biophysics and structural biology at the University of California, Berkeley.
Help employers find you! Check out all the jobs and post your resume.
